Cartesian Therapeutics公司宣布,已从K2 HealthVenture获得高达1.5亿美元的非稀释性融资。公司预计,针对重症肌无力的三期Aurora临床试验的顶线数据将在2027年第一季度公布。此外,公司计划在2027年年中提交生物制品许可申请。
Cartesian Therapeutics公司宣布,已从K2 HealthVenture获得高达1.5亿美元的非稀释性融资。公司预计,针对重症肌无力的三期Aurora临床试验的顶线数据将在2027年第一季度公布。此外,公司计划在2027年年中提交生物制品许可申请。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.